Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u347700914/domains/themoneyoffice.com/public_html/wp-includes/functions.php on line 6121

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
SELECT a.action_id FROM TM_actionscheduler_actions a LEFT JOIN TM_actionscheduler_groups g ON g.group_id=a.group_id WHERE 1=1 AND g.slug='image-optimization/cleanup' AND a.hook='image-optimization/cleanup/stuck-operation' AND a.args='[]' AND a.status IN ('pending') ORDER BY a.scheduled_date_gmt ASC LIMIT 0, 1

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_groups' doesn't exist]
SELECT group_id FROM TM_actionscheduler_groups WHERE slug='image-optimization/cleanup'

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_groups' doesn't exist]
SHOW FULL COLUMNS FROM `TM_actionscheduler_groups`

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
INSERT INTO TM_actionscheduler_actions ( `hook`, `status`, `scheduled_date_gmt`, `scheduled_date_local`, `schedule`, `group_id`, `priority`, `args` ) SELECT 'image-optimization/cleanup/stuck-operation', 'pending', '2025-06-27 01:18:42', '2025-06-27 02:18:42', 'O:32:\"ActionScheduler_IntervalSchedule\":5:{s:22:\"\0*\0scheduled_timestamp\";i:1750987122;s:18:\"\0*\0first_timestamp\";i:1750987122;s:13:\"\0*\0recurrence\";i:300;s:49:\"\0ActionScheduler_IntervalSchedule\0start_timestamp\";i:1750987122;s:53:\"\0ActionScheduler_IntervalSchedule\0interval_in_seconds\";i:300;}', 0, 10, '[]' FROM DUAL WHERE ( SELECT NULL FROM DUAL ) IS NULL

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
SELECT a.action_id FROM TM_actionscheduler_actions a WHERE 1=1 AND a.hook='action_scheduler/migration_hook' AND a.status IN ('in-progress') ORDER BY a.scheduled_date_gmt ASC LIMIT 0, 1

WordPress database error: [Table 'u347700914_MNO.TM_actionscheduler_actions' doesn't exist]
SELECT a.action_id FROM TM_actionscheduler_actions a WHERE 1=1 AND a.hook='action_scheduler/migration_hook' AND a.status IN ('pending') ORDER BY a.scheduled_date_gmt ASC LIMIT 0, 1

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 – All about Money
X-twitter Facebook Linkedin Instagram
Submit Guest Post
SUBMIT MUSIC
SUBMIT POST
SUBMIT MUSIC
X-twitter Facebook Linkedin Instagram

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Clearside Biomedical, Inc.

Clearside Biomedical, Inc.

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-645-4404 (U.S.) or 862-298-0702 (international) and requesting the Clearside call. The Company suggests participants join 15 minutes in advance of the event.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

Share this article

Picture of Moneyofficeteam

Moneyofficeteam

Read All News

Subscribe

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Latest News

Featured Categories

More News

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Where Every Story Makes Headlines

We uphold the highest standards of journalistic integrity and ethical reporting, ensuring that truth and transparency prevail in all our content.

Facebook-f X-twitter Linkedin-in Instagram Youtube Threads

Trending News

Popular Categories

Information

Our Sister Websites

themoneyofficeappstore.com
bestworldevent.com
thebestworldevents.com
  • 2025
  • All about Money.
  • All rights reserved.